ArticleFrontiers in immunology2025

Case Report: dose adjustment of orelabrutinib for managing central nervous system post-transplant lymphoproliferative disorder following acute lymphoblastic leukemia transplantation.

Wenwen Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.